We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App





Rapid COVID-19 Variant Test Speeds SARS-CoV-2 Mutation Tracking From Weeks to Hours

By LabMedica International staff writers
Posted on 23 Sep 2021
Print article
Illustration
Illustration

Efforts by researchers to identify and track variants of the SARS-CoV-2 virus has led to the creation and future implementation of a new method to “fingerprint” all currently known COVID-19 mutations.

The method developed by researchers at the UW School of Medicine (Seattle, Wash., (USA) identifies the presence of dozens of mutations at once and requires only three ingredients: a dipstick, a common thermocycler instrument, and a processed test sample. Upon coming into contact with the sample, the dipstick records which variant is present by exposing a series of lines, or bands. Every known variant of interest and concern has a correlating band pattern, which the test administrator can match to the sample.

Currently the definitive method of tracking variants of the virus, including the delta variant, is done through genomic sequencing. The process is thorough but can take up to two weeks to collect a sufficiently large batch of samples and yield results. The new method provides high-resolution results much more quickly, with a single or a few samples in hand. A grant awarded through the National Institutes of Health is fueling the development of the test, which will also include a barcode component that can be scanned through a smartphone app. The app connects the user to a database of all variant fingerprints. Preprogrammed and battery-capable thermocyclers will also be made available for distribution with test materials.

The test is already available as a prototype in the form of a same-day to next-day service in the UW School of Medicine lab on a collaborative basis, while a wider distribution of the full kit for clinical epidemiologists and researchers could come by this winter. The method is also designed with a key ability: potentially tracking new variants as they emerge, according to the researchers.

“It's a rapid test. We can identify the variant within two hours of the sample being in hand,” said UW School of Medicine Microbiology Professor Evgeni Sokurenko. “With emergence of new variants, generally, what we see right now involves a new combination of the known mutations. So we will be able to detect with this test, [the] emergence of new combinations of mutations, meaning new variants.”

Related Links:

UW School of Medicine

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)

Print article
77 ELEKTRONIKA

Channels

Clinical Chemistry

view channel
Image: PhD student and first author Tarek Eissa has analyzed thousands of molecular fingerprints (Photo courtesy of Thorsten Naeser / MPQ / Attoworld)

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Infrared spectroscopy, a method using infrared light to study the molecular composition of substances, has been a foundational tool in chemistry for decades, functioning similarly to a molecular fingerprinting... Read more

Molecular Diagnostics

view channel
Image: Researchers have found the first evidence of testing for the alpha-synuclein protein in blood samples via seed amplification assay (Photo courtesy of Shutterstock)

Blood Test to Detect Alpha-Synuclein Protein Could Revolutionize Parkinson's Disease Diagnostics

Currently, Parkinson's disease (PD) is identified through clinical diagnosis, typically at a later stage in the disease's progression. There is a pressing need for an objective and quantifiable biomarker... Read more

Hematology

view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more

Immunology

view channel
Image: The blood test measures lymphocytes  to guide the use of multiple myeloma immunotherapy (Photo courtesy of 123RF)

Simple Blood Test Identifies Multiple Myeloma Patients Likely to Benefit from CAR-T Immunotherapy

Multiple myeloma, a type of blood cancer originating from plasma cells in the bone marrow, sees almost all patients experiencing a relapse at some stage. This means that the cancer returns even after initially... Read more

Microbiology

view channel
Image: Ultra-Rapid Antimicrobial Susceptibility Testing (uRAST) revolutionizing traditional antibiotic susceptibility testing (Photo courtesy of Seoul National University)

Ultra-Rapid Culture-Free Sepsis Test Reduces Testing Time from Days to Hours

Sepsis, a critical emergency condition, results from an overactive inflammatory response to pathogens like bacteria or fungi in the blood, leading to organ damage and the possibility of sudden death.... Read more

Pathology

view channel
Image: The AI model can distinguish different stages of DCIS from inexpensive and readily available breast tissue images (Photo courtesy of David A. Litman/Shutterstock)

AI Model Identifies Breast Tumor Stages Likely To Progress to Invasive Cancer

Ductal carcinoma in situ (DCIS) is a non-invasive type of tumor that can sometimes progress to a more lethal form of breast cancer and represents about 25% of all breast cancer cases. Between 30% and 50%... Read more

Industry

view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.